China’s vaccine landscape is shifting after local biotech Xiamen Innovax Biotech unveiled the country’s first domestically ...

A draft agenda for an upcoming meeting of CDC vaccine experts indicated on Wednesday that there would be no discussion about human papillomavirus (HPV) vaccines, a move favorable to Merck (NYSE ...

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...

Merck (MRK) stock gains as CDC's draft agenda for an upcoming meeting excludes HPV vaccine dose changes, favoring the company's Gardasil vaccine. Read more here.

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.